Conditions: Pancreatic Neoplasm Pituitary Neoplasm Nelson Syndrome Ectopic ACTH Syndrome
Keywords: Rare tumors of neuroendocrine origin NETs of the pancreatic Pituitary NETs EAS Tumors Nelson's Syndrome Pancreatic neoplasm pituitary neoplasm Nelson Syndrome ectopic ACTH syndrome pasireotide LAR PNETs PiNETS
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 118
Healthy volunteers: no

Brief summary:
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.

Detailed description:

Arms:
arm 1: Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.

Interventions: intervention 1: pasireotide LAR
Intervention descriptions: intervention 1: Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.

Protocol document: